Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 15

1.

Activated STAT3 as a correlate of distant metastasis in prostate cancer: a secondary analysis of Radiation Therapy Oncology Group 86-10.

Torres-Roca JF, DeSilvio M, Mora LB, Khor LY, Hammond E, Ahmad N, Jove R, Forman J, Lee RJ, Sandler H, Pollack A.

Urology. 2007 Mar;69(3):505-9.

PMID:
17382154
2.

A novel platinum compound inhibits constitutive Stat3 signaling and induces cell cycle arrest and apoptosis of malignant cells.

Turkson J, Zhang S, Mora LB, Burns A, Sebti S, Jove R.

J Biol Chem. 2005 Sep 23;280(38):32979-88. Epub 2005 Jul 26.

3.

Inhibition of constitutive signal transducer and activator of transcription 3 activation by novel platinum complexes with potent antitumor activity.

Turkson J, Zhang S, Palmer J, Kay H, Stanko J, Mora LB, Sebti S, Yu H, Jove R.

Mol Cancer Ther. 2004 Dec;3(12):1533-42.

4.

Deregulated expression of LRBA facilitates cancer cell growth.

Wang JW, Gamsby JJ, Highfill SL, Mora LB, Bloom GC, Yeatman TJ, Pan TC, Ramne AL, Chodosh LA, Cress WD, Chen J, Kerr WG.

Oncogene. 2004 May 20;23(23):4089-97.

PMID:
15064745
5.

Inhibition of Bcr-Abl kinase activity by PD180970 blocks constitutive activation of Stat5 and growth of CML cells.

Huang M, Dorsey JF, Epling-Burnette PK, Nimmanapalli R, Landowski TH, Mora LB, Niu G, Sinibaldi D, Bai F, Kraker A, Yu H, Moscinski L, Wei S, Djeu J, Dalton WS, Bhalla K, Loughran TP, Wu J, Jove R.

Oncogene. 2002 Dec 12;21(57):8804-16.

6.

Combination therapy with AG-490 and interleukin 12 achieves greater antitumor effects than either agent alone.

Burdelya L, Catlett-Falcone R, Levitzki A, Cheng F, Mora LB, Sotomayor E, Coppola D, Sun J, Sebti S, Dalton WS, Jove R, Yu H.

Mol Cancer Ther. 2002 Sep;1(11):893-9.

7.

Constitutive activation of Stat3 in human prostate tumors and cell lines: direct inhibition of Stat3 signaling induces apoptosis of prostate cancer cells.

Mora LB, Buettner R, Seigne J, Diaz J, Ahmad N, Garcia R, Bowman T, Falcone R, Fairclough R, Cantor A, Muro-Cacho C, Livingston S, Karras J, Pow-Sang J, Jove R.

Cancer Res. 2002 Nov 15;62(22):6659-66.

8.

Activated STAT signaling in human tumors provides novel molecular targets for therapeutic intervention.

Buettner R, Mora LB, Jove R.

Clin Cancer Res. 2002 Apr;8(4):945-54. Review.

9.

Prostate adenocarcinoma: cellular and molecular abnormalities.

Mora LB, Buettner R, Ahmad N, Bassel Y, Jove R, Seigne JD.

Cancer Control. 2001 Nov-Dec;8(6):551-61. Review. No abstract available.

PMID:
11807425
10.

Cytometric analysis of Fas and Bcl-2 expression in normal prostatic epithelium and prostate cancer.

Diaz JI, Pow-Sang JM, Mora LB, Seigne JD, Cantor AB, Dalton WS.

Urol Oncol. 2000 Jul 1;5(4):149-154.

PMID:
10869956
11.

Stage B Prostate Cancer: Correlation of DNA Ploidy Analysis With Histological and Clinical Parameters.

Mora LB, Moscinski LC, Diaz JI, Blair P, Cantor AB, Pow-Sang JM.

Cancer Control. 1999 Nov;6(6):587-591.

PMID:
10756390
12.

The Mainz Classification of Renal Cell Tumors.

Diaz JI, Mora LB, Hakam A.

Cancer Control. 1999 Nov;6(6):571-579.

PMID:
10756388
13.
14.

Predictability of PSA failure in prostate cancer by computerized cytometric assessment of tumoral cell proliferation.

Diaz JI, Mora LB, Austin PF, Muro-Cacho CA, Cantor AB, Nicosia SV, Pow-Sang JM.

Urology. 1999 May;53(5):931-8.

PMID:
10223486
15.

Ancillary techniques in the followup of transitional cell carcinoma: a comparison of cytology, histology and deoxyribonucleic acid image analysis cytometry in 91 patients.

Mora LB, Nicosia SV, Pow-Sang JM, Ku NK, Diaz JI, Lockhart J, Einstein A.

J Urol. 1996 Jul;156(1):49-54; discussion 54-5.

PMID:
8648836

Supplemental Content

Support Center